Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 35 USD -0.93% Market Closed
Market Cap: 3.1B USD

Travere Therapeutics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Travere Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Travere Therapeutics Inc
NASDAQ:TVTX
EPS (Diluted)
$0
CAGR 3-Years
41%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

Travere Therapeutics Inc
Glance View

Market Cap
3.1B USD
Industry
Biotechnology

Travere Therapeutics Inc., a biopharmaceutical trailblazer, has carved a niche in the healthcare landscape by focusing on the often-overlooked realm of rare diseases. With a mission to improve the lives of patients grappling with conditions that lack sufficient treatment options, Travere leverages its deep expertise in research, development, and commercialization of therapies. Beyond generic pharmaceuticals, the company's extensive pipeline is filled with innovative treatments, targeting conditions from chronic kidney diseases to rare liver disorders. This strategic emphasis on rare diseases not only exemplifies Travere's commitment to social responsibility but also positions it uniquely within the competitive pharmaceutical sector, where the rarity of these conditions often results in limited competition. The financial lifeline of Travere Therapeutics comes from its ability to navigate the intricate process of bringing drugs from conception to market. Revenue streams are primarily driven by the sales of FDA-approved products, alongside milestone and royalty payments tied to strategic collaborations. The company’s shrewd strategy involves acquiring or licensing promising compounds and utilizing its robust in-house capabilities to carry these assets through clinical trials. This intertwined web of internal development and strategic partnerships creates a sustainable business model. It ensures that as current treatments mature and stabilize their market presence, new pipeline products are continually groomed, keeping revenue streams dynamic while reinforcing their commitment to addressing unmet medical needs.

TVTX Intrinsic Value
44.92 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Travere Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-0.9 USD

Based on the financial report for Sep 30, 2025, Travere Therapeutics Inc's EPS (Diluted) amounts to -0.9 USD.

What is Travere Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
11%

Over the last year, the EPS (Diluted) growth was 81%. The average annual EPS (Diluted) growth rates for Travere Therapeutics Inc have been 41% over the past three years , 11% over the past five years .

Back to Top